Trivastal (piribedil) / Servier  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trivastal (piribedil) / Servier
2005-002010-38: Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study

Completed
3
40
Europe
Trivastal, S 90049,
Institut de Recherches Internationales Servier (I.R.I.S.)
Advanced ParkinsonĀ“s Disease
 
 

Download Options